🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation

RecruitingNAAges 18 Years - anyAllXiaotong Hou
NCT06275555 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this study was to evaluate the efficacy and safety of bivalirudin in anticoagulation therapy in patients with extracorporeal membrane oxygenation (ECMO) compared with unfractionated heparin.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age ≥ 18 years old 2. Accept VA-ECMO or VV-ECMO 3. the ECMO team believes that systemic anticoagulation is necessary and that APTT should be maintained at 40-60s. 4. sign the informed consent form Exclusion Criteria: 1. previous history of allergy to heparin or bivalirudin 2. previous diagnosis of heparin-induced thrombocytopenia. 3. the pre-random ECMO assistance time is more than 48 hours. 4. pregnant female 5. have participated in this study before. 6. the researchers believe that there are other factors that are not suitable to participate in this study.
💊

What it tests

  • bivalirudin
  • unfractionated heparin
📍

Where

1 site
Beijing Anzhen Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy